Yim 2018.

Methods	Randomised clinical trial
Participants	Country: South Korea Period of recruitment: not stated Number randomised: 124 Postrandomisation dropouts: 12 (9.7%) Revised sample size: 112 Reasons for postrandomisation dropouts: not stated Mean age (years): not stated Females: not stated Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or variceal bleeding): not stated Ascites with low protein: not stated Primary prophylaxis: not stated Alcohol‐related cirrhosis: not stated Viral‐related cirrhosis: not stated Autoimmune disease‐related cirrhosis (e.g. PSC, PBC, AIH): not stated Other causes for cirrhosis: not stated Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated Exclusion criteria: hypersensitivity or intolerability with quinolones hepatocellular carcinoma beyond Milan Criteria hepatic encephalopathy > stage 2 history of treatment with antibiotics within 2 weeks of enrolment HIV infection uncontrolled malignancy women at child‐bearing age unwilling to use effective measures for contraception pregnant or breast‐feeding women
Interventions	Participants randomly assigned to 2 groups. Group 1: ciprofloxacin (n = 57) Further details: ciprofloxacin 750 mg weekly for 12 months Group 2: norfloxacin (n = 55) Further details: norfloxacin 400 mg daily for 12 months Additional details: none of baseline characteristics were extracted as the outcomes were presented for 55 vs 57 participants, but the baseline characteristics were described for 62 participants in each group.
Outcomes	Outcomes reported: all‐cause mortality; number of serious adverse events per participant; liver transplantation; proportion with spontaneous bacterial peritonitis (as per definition) Follow‐up (months): 12
Notes	Trial name/trial registry number: NCT01542801 Attempted to contact authors in November 2018, but received no replies.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "The randomization table was generated by a statistician (SSK) using the nQuery Advisor program."
Allocation concealment (selection bias)	Low risk	Quote: "Centralized web‐based interactive response system."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Open‐label"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "Open‐label"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: there were postrandomisation dropouts and it was unclear whether these were related to outcomes.
Selective reporting (reporting bias)	High risk	Comment: protocol not available, and authors did not report the outcomes assessed adequately.
Other bias	Low risk	Comment: no other bias noted

AIH: autoimmune hepatitis; BD: twice daily; n: number of participants; OD: once daily; PBC: primary biliary cirrhosis; PSC: primary sclerosing cholangitis; TDS: three times daily.